|
|
|
Price: $0.1410
$0.00 
-0.704%
|
| Day's High:
| $0.155
| Week Perf:
| -8.86 %
|
| Day's Low: |
$ 0.13 |
30 Day Perf: |
-14.02 % |
| Volume (M): |
568 |
52 Wk High: |
$ 2.18 |
| Volume (M$): |
$ 80 |
52 Wk Avg: |
$0.76 |
| Open: |
$0.15 |
52 Wk Low: |
$0.12 |
|
|
| Market Capitalization (Millions $) |
13 |
| Shares
Outstanding (Millions) |
90 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
744 |
| Net Income (TTM) (Millions $) |
-225 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
41 |
Akumin Inc
Company Address: 8300 W. Sunrise Boulevard Plantation 33322 FL
Company Phone Number: 730-0050 Stock Exchange / Ticker: NASDAQ AKU
| AKU is expected to report next financial results on November 08, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Aclarion Inc
In this bearish article, we will examine Aclarion Inc's financial performance, primarily focusing on the financial time-frame closing on June 30, 2023, and its implications for the company's future. Despite an impressive revenue growth of 59.91%, there are underlying concerns that cannot be ignored. Additionally, recent trading activity and the stock's year-to-date performance indicate a declining trend. This article aims to highlight and explain these issues.
Financial Results and Revenue Growth:
Aclarion Inc showcased balanced books of $0.00 per share for the financial time-frame closing June 30, 2023. While this might initially seem positive from a profitability standpoint, it is vital to note that it remains unchanged both from the previous year and the prior reporting season. This stagnant performance raises concerns about Aclarion's ability to generate consistent profits.
|
|
Delwinds Insurance Acquisition Corp
Medical Laboratories Company Reports Modest Revenue in Q2 2023 Earnings Season
In the latest quarterly financial report released by the Medical Laboratories company, it has been revealed that the company generated revenue amounting to $0.012 million during the second quarter of the 2023 earnings season. While this figure may seem modest, it reflects the company's ongoing efforts to navigate the challenging market conditions currently impacting the healthcare industry.
Despite the relatively low revenue, Medical Laboratories remains focused on its core competencies and continues to deliver quality services to its clients. The company's strong reputation in the market has allowed it to maintain a steady stream of business, despite the headwinds it faces.
|
|
Invitae Corporation
Introduction
Invitae Corporation, a prominent player in the Medical Laboratories sector, reported disappointing financial results for the April to June 30 2023 time-frame. The company's earnings per share (EPS) declined to $-0.78, compared to $-10.87 a year earlier, representing a significant increase in losses. Furthermore, revenue plummeted by 11.777% to $120.53 million from $136.62 million in the prior year, while sequentially increasing by a meager 2.706% from $117.36 million.
Revenue Contrast
Contrasting with the growth observed in the remainder of the Medical Laboratories sector, which recorded a revenue increase of 3.98% in the second quarter of 2023 compared to the same reporting period a year ago, Invitae Corporation suffered a substantial decrease in revenue. This decline puts the company at a clear disadvantage within its industry, indicating a failure to adapt to current market trends and potential internal inefficiencies.
|
|
Bionexus Gene Lab Corp
Bionexus Gene Lab Corp (BGLC) recently released its financial results for the second quarter of 2023. In order to understand the implications of these results and their potential effects on the company's future, it is crucial to delve deeper into the figures and analyze them in the context of the overall medical laboratories sector.
Revenue Growth and Comparison:
During the second quarter of 2023, BGLC's revenue witnessed a slight increase of 3.289% to reach $2.57 million. This should be seen in relation to the corresponding period a year earlier, when the company generated $2.49 million in revenue. Furthermore, Q2 2023 revenue also recorded a sequential growth of 7.978% from $2.38 million.
|
|
Biocept Inc
Biocept Inc (BIOC) has recently released its second-quarter financial report for 2023, and the results are disastrous. The company's revenue plummeted by a staggering -94.449% to a mere $0.59 million. This significant decline in revenue is alarming, especially when compared to the rest of the Medical Laboratories sector, which experienced revenue growth during the same period.
Furthermore, the company's shortfall per share has widened to $-3.50, a considerable deterioration from the previous year's reporting season. In comparison to the prior reporting season, revenue deteriorated sequentially by -12.481% from $0.67 million.
|
| Per Share |
Current |
| Earnings (TTM) |
-2.52 $ |
| Revenues (TTM) |
8.23 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.42 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.52 $
|
| Revenues (TTM) |
8.23 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.42 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
